There were no significant differences in the rate of SARS-CoV-2 infection between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics in the confirmed cases group (RR: 1.04; 95% CI: 0.64-1.69; P = 0.89) and in the suspected cases group (RR: 1.27; 95% CI: 0.52-3.12; P = 0.60), respectively (Figure 5A). The gene discussed is IL17A; the disease is psoriasis.